Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
59 Results for "
complement pathway
" in MedChemExpress (MCE) Product Catalog:
Products (59)
59 Results for "complement pathway" in MCE Product Catalog:
Cat. No.: HY-P5528
Cat. No.: HY-NP0194B
and non-immune cells. C1q Protein (rabbit) can be used for the research of mutiple disease .
Cat. No.: HY-E70390
Synonyms: masp-2, c1 esterase, c1-esterase
Target:
Research Areas:
C1s Enzyme is a subunit of the complement C1 complex, which activates the complement as a serine protease. C1s Enzyme cleaves LRP5 and LRP6, and thus activates the Wnt/β-Catenin signaling pathway. C1s Enzyme promotes the macrophage M2 polarization and inhibits M1 polarization. C1s Enzyme enhances efferocytosis, exhibits anti-inflammatory activity .
Cat. No.: HY-P990955
CAS No.: 2839652-75-2
Synonyms: ADX-097
Target:
Research Areas:
Cat. No.: HY-N21519
CAS No.: 2193052-99-0
Target:
Cat. No.: HY-P992456
Target:
Research Areas:
SAR-443809 is a monoclonal antibody targeting complement factor Bb that inhibits the alternative complement pathway. SAR-443809 blocks the cleavage of C3 and factor B via selective binding to the activated form factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for research on hematological and renal disorders mediated by abnormal alternative complement pathway activity .
Cat. No.: HY-P991022
CAS No.: 2842046-67-5
Synonyms: NM8074
Target:
Research Areas:
Cat. No.: HY-P992463
Target:
Research Areas:
Cat. No.: HY-N19128
CAS No.: 1476801-10-1
Target:
Cat. No.: HY-P991954
Target:
Research Areas:
Cat. No.: HY-P992512
Target:
Research Areas:
Cat. No.: HY-N7955
CAS No.: 372096-70-3
Category:
Actaea heracleifolia (Kom.) J. Compton Tetracyclic Triterpenoids Terpenoids Ranunculaceae Plants
Target:
Target:
Research Areas:
Solasulfone (Solapsone; Sulfetrone) is an inhibitor of complement protein C1q and β-lactamase. Solasulfone also acts as a chemotherapeutic agent and can be used in cancer research .
Cat. No.: HY-127105B
CAS No.: 1644670-38-1
Synonyms: LNP023 TFA
Target:
Research Areas:
Iptacopan (LNP023) TFA is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan TFA exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan TFA can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
Cat. No.: HY-P992349
Cat. No.: HY-N17326
CAS No.: 242794-72-5
Cat. No.: HY-185926
CAS No.: 2364414-05-9
Synonyms: NOX-D21; AON-D21
Research Areas:
Ldalaptican pegol (AON-D21; NOX-D21) is a PEGylated mixed RNA/DNA L-aptamer that specifically binds to complement C5a. Ldalaptican pegol binds to C5a and the C5a moiety on uncleaved C5, thereby blocking C5a signaling. This inhibition suppresses downstream inflammatory responses, immune cell infiltration and chemotaxis, the release of pro-fibrotic factors, and abnormalities in lipid metabolism signaling pathways. Ldalaptican pegol can also alleviate allograft rejection. Ldalaptican pegol can be used in research on inflammatory muscle diseases, Duchenne muscular dystrophy (DMD), diabetes, renal fibrosis, and allograft organ transplant rejection .
Cat. No.: HY-P10868A
Synonyms: RLS-0071 TFA
Target:
Research Areas:
Cat. No.: HY-L001P
32,925 compounds
Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype.
MCE owns a unique collection of 32,925 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. This library is a useful tool for signal pathway research, drug discovery and drug repurposing, etc.
Bioactive Compound Library Plus, with more powerful screening capability, further complements Bioactive Compound Library (HY-L001) by adding some compounds with low solubility or solution stability (Part B) and some novel, rare or exclusive compounds (Part C) to this library. Overall, bioactive compound library plus (HY-L001P) includes tree parts: Part A, Part B and Part C. Compounds in Part A are equal to the products in HY-L001, which can be supplied in solution or solid form. Compounds in Part B and C are only supplied in solid form.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
